Old drug, new hope? spironolactone trial targets lung blood vessel damage
NCT ID NCT01712620
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 10 times
Summary
This phase 2 study tests whether spironolactone, a drug already used for fluid retention, can improve exercise capacity and blood vessel function in people with pulmonary arterial hypertension (PAH). About 70 adults with PAH will receive either spironolactone or a placebo for 24 weeks. Researchers will measure changes in walking distance and heart-lung function to see if the drug reduces inflammation and vessel damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Spironolactone
- What this could lead to
- If it works, this could point toward a new use for spironolactone to improve exercise ability and blood vessel health in people with pulmonary arterial hypertension.
- What could go wrong
- This is a small, early-phase pilot study, so results may not be definitive. Spironolactone can cause side effects like high potassium levels, kidney issues, or breast tenderness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests